Immunogenicity and safety of Cervarix HPV-16/18 AS04-adjuvant vaccine against HPV induced cervical cancer in women (15+ years)
DOI:
https://doi.org/10.33178/SMJ.2023.1.5Keywords:
HPV, human papilloma virus, HPV vaccine, cervical cancerAbstract
Background: The incidence of cervical cancer has decreased by over 50% from the mid-1970s to the mid-2000s. This is due in part to an increase in screening, which can identify cervical changes before they turn cancerous. Decreasing incidence rates in young women may be due to the use of the HPV vaccine. There are currently three types of HPV vaccines on the market: bivalent, quadrivalent and nine-valent HPV vaccines. These are administered in three-doses to both sexes from age 15 upwards to prevent HPV infection. Many medical systems support the vaccination of teenage girls and boys with HPV vaccines during their secondary school years in order to reduce the incidence of HPV-related cervical cancer in women. Despite the discovery of the link between HPV and cervical cancer in 1985, the beginning of vaccine production in 2002, and promotion of screening procedures since the 1960’s, cervical cancer is still the fourth most common cancer in women worldwide today.
Objective: This review aims to analyse the immunogenicity and safety of Cervarix®, also known as HPV-16/18 AS04-adjuvant vaccine, in women (15+ years) against cervical cancer.
Methods: The literature review analysing the effectiveness and immunogenicity of HPV-16/18 AS04-ADJUVANTED Vaccine against cervical cancer, was conducted by using two main databases: EbescoHost (Medline and Academic Search) and PubMed. Advanced searches were conducted using specific key words, various filters and Boolean operators ‘OR’ and ‘AND’ to find the most suitable literature. This process resulted in over 100 results. From this cohort, clinical trials were selected in accordance with the specific inclusion and exclusion criteria determined for the review. After duplicates from both databases were removed, the studies were assessed in order or title, population and objective relevance, and the top 10 most relevant articles to the title of the literature review, were selected for the literature review.
Results: The 10 clinical trials selected all obtained a minimum of 10 out of the 11 CASP requirements indicating good study quality. All 10 studies were successful in proving the immunogenicity and safety of the HPV-16/18 AS04-adjuvant vaccine in protecting women 15+ (15-55 years) from developing HPV-induced cervical cancer [15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. This confers that vaccination against HPV-16/18 virus proves to be effective in preventing HPV-induced CIN and cervical cancer and is a safe to administer vaccine.
References
Cervical Cancer: Statistics | Cancer.Net [Internet]. [cited 2021 Nov 10]. Available from: https://www.cancer.net/cancer-types/cervical-cancer/statistics
Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. Journal of the National Medical Association [Internet]. 2020 Apr;112[2]:229–32. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0027968420300432
CASP_RCT_Checklist_PDF_Fillable_Form.
Cervical Cancer: An NCD We Can Overcome [Internet]. [cited 2021 Nov 9]. Available from: https://www.who.int/directorgeneral/speeches/detail/cervical-cancer-an-ncd-we-can-overcome
Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. Journal of Clinical Medicine [Internet]. 2021 Sep 29 [cited 2021 Nov 9];10[19]:4523. Available from: https://www.mdpi.com/20770383/10/19/4523
Cervical cancer [Internet]. [cited 2021 Nov 9]. Available from: https://www.who.int/health-topics/cervical-cancer#tab=tab_1
Cervarix HPV vaccine can cut cervical cancer rates by almost 90%, new study says [Internet]. [cited 2021 Nov 9]. Available from: https://www.thejournal.ie/hpv-vaccine-effectiveness-study-the-lancet-5590855-Nov2021/
Panatto D, Amicizia D, Trucchi C, Casabona F, Lai PL, Bonanni P, et al. Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health [Internet]. 2012 [cited 2021 Nov 24];12[1]:623. Available from: /pmc/articles/PMC3490840/
Who should have cervical screening - HSE.ie [Internet]. [cited 2021 Nov 24]. Available from: https://www2.hse.ie/screening-and-vaccinations/cervical-screening/when-you-should-have-cervical-screening/who-should-have-cervical-screening.html
Treatment decisions | Cervical cancer | Cancer Research UK [Internet]. [cited 2021 Nov 9]. Available from: https://www.cancerresearchuk.org/about-cancer/cervical-cancer/treatment/treatment-decisions
Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. Journal of Biomedical Science [Internet]. 2016 Nov 4 [cited 2021 Nov 9];23[1]:1–19. Available from: https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-016-0293-9
HPV Vaccination: What Everyone Should Know | CDC [Internet]. [cited 2021 Nov 9]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/public/index.html
McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus [HPV] types 16 and 18 vaccine [Cervarix®]: a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs [Internet]. 2011 Mar 5 [cited 2021 Nov 9];71[4]:465–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21395359
Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines [Internet]. 2020 Jul 16;8[3]:391. Available from: https://www.mdpi.com/2076-393X/8/3/391
Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. Journal of Obstetrics and Gynaecology Research [Internet]. 2010 Feb;36[1]:123–32. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1447-0756.2009.01167.x
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009 Jan 22;27[4]:581–7.
Konno R, Yoshikawa H, Okutani M, Quint W, v Suryakiran P, Lin L, et al. Efficacy of the human papillomavirus [HPV]-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Human Vaccines & Immunotherapeutics. 2014 Jul 7;10[7].
Naud PS, Roteli-Martins CM, de Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Human vaccines & immunotherapeutics [Internet]. 2014 Aug 1 [cited 2021 Nov 16];10[8]:2147–62. Available from: https://pubmed.ncbi.nlm.nih.gov/25424918/
Ngan HYS, Cheung ANY, Tam KF, Chan KKL, Tang HW, Bi D, et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine:
immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong medical journal = Xianggang yi xue za zhi. 2010 Jun;16[3].
Wheeler CM, Skinner SR, del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet Infectious diseases [Internet]. 2016 Oct 1 [cited 2021 Nov 16];16[10]:1154–68. Available from: https://pubmed.ncbi.nlm.nih.gov/27373900/
Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, et al. Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Cervical Cancer Vaccine in Malaysian Women Aged 18–35 years: A Randomized Controlled Trial.
Zhu F, Hu S-Y, Hong Y, Hu Y-M, Zhang X, Zhang Y-J, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial. Cancer Medicine. 2017 Jan;6[1].
Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study. Vaccine [Internet]. 2013 Nov 19 [cited 2021 Nov 16];31[48]:5745–53. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0264410X13012735
Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine:
Immunogenicity and safety in 15-25 years old healthy Korean women. Journal of Gynecologic Oncology. 2011;22[2]:67–75.
FDA Licensure of Bivalent Human Papillomavirus Vaccine [HPV2, Cervarix] for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices [ACIP] [Internet]. [cited 2021 Nov 25]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
Side Effects of Cervarix [Human Papillomavirus Bivalent Vaccine], Warnings, Uses [Internet]. [cited 2021 Nov 25]. Available from: https://www.rxlist.com/cervarix-side-effects-drug-center.htm
Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. International Journal of Behavioural and Healthcare Research.
;2[4]:320.
Downloads
Published
License
Copyright (c) 2024 Adina Elena Zagoneanu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
